PE20021084A1 - Ciclobuten-1,2-dionas 3,4-di-substituidas como ligandos del receptor de cxc-quimiocina - Google Patents

Ciclobuten-1,2-dionas 3,4-di-substituidas como ligandos del receptor de cxc-quimiocina

Info

Publication number
PE20021084A1
PE20021084A1 PE2002000318A PE2002000318A PE20021084A1 PE 20021084 A1 PE20021084 A1 PE 20021084A1 PE 2002000318 A PE2002000318 A PE 2002000318A PE 2002000318 A PE2002000318 A PE 2002000318A PE 20021084 A1 PE20021084 A1 PE 20021084A1
Authority
PE
Peru
Prior art keywords
cyclobuten
cxc
substituted
dionas
ligands
Prior art date
Application number
PE2002000318A
Other languages
English (en)
Inventor
Richard W Bond
Michael Dwyer
Johan A Ferreira
Jianhua Chao
Cynthia J Aki
Younong Yu
Ge Li
Nelson
J Robert Merrit
Bernd Kaiser
Laura Rokosz
Arthur G Taveras
John J Baldwin
Jianping Chao
Original Assignee
Schering Corp
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Drug Discovery filed Critical Schering Corp
Publication of PE20021084A1 publication Critical patent/PE20021084A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

SE FERIERE A CICLOBUTEN-1,2-DIONAS 3,4-DI-SUBSTITUIDAS DE FORMULA I DONDE A ES EL GRUPO a, b, ENTRE OTROS; R7 Y R8 SON H, ALQUILO, ARILO, HETEROARILO, HETEROARILALQUILO, ENTRE OTROS; R9 ES R7, R8, HALOGENO, CF3, -COR7, -OR7, ENTRE OTROS; B ES EL GRUPO a, ENTRE OTROS; R2 ES H, OH, C(O)OH, SH, ENTRE OTROS; R3 Y R4 SON H, HALOGENO, ALQUILO, ALCOXI, ENTRE OTROS; R5 Y R6 SON H, HALOGENO, ALQUILO, ALCOXI, ENTRE OTROS. LOS COMPUESTOS DE FORMULA I SON LIGANDOS DEL RECEPTOR DE CXC-QUIMIOCINA Y SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS
PE2002000318A 2001-04-16 2002-04-16 Ciclobuten-1,2-dionas 3,4-di-substituidas como ligandos del receptor de cxc-quimiocina PE20021084A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28402601P 2001-04-16 2001-04-16

Publications (1)

Publication Number Publication Date
PE20021084A1 true PE20021084A1 (es) 2002-12-20

Family

ID=23088576

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000318A PE20021084A1 (es) 2001-04-16 2002-04-16 Ciclobuten-1,2-dionas 3,4-di-substituidas como ligandos del receptor de cxc-quimiocina

Country Status (30)

Country Link
EP (2) EP1818325B1 (es)
JP (3) JP4499993B2 (es)
KR (2) KR100952531B1 (es)
CN (2) CN1289471C (es)
AR (1) AR035825A1 (es)
AT (2) ATE458715T1 (es)
AU (3) AU2002311841B2 (es)
BR (1) BRPI0208957B8 (es)
CA (1) CA2444031C (es)
CY (2) CY1109908T1 (es)
CZ (1) CZ20032831A3 (es)
DE (2) DE60220778T2 (es)
DK (2) DK1818325T3 (es)
EC (1) ECSP034809A (es)
ES (2) ES2287284T3 (es)
HU (1) HUP0401783A3 (es)
IL (3) IL158262A0 (es)
MX (1) MXPA03009441A (es)
MY (2) MY149050A (es)
NO (2) NO330790B1 (es)
NZ (3) NZ543869A (es)
PE (1) PE20021084A1 (es)
PL (2) PL207255B1 (es)
PT (2) PT1818325E (es)
RU (1) RU2344123C9 (es)
SI (2) SI1381590T1 (es)
SK (1) SK287598B6 (es)
TW (2) TW200736196A (es)
WO (1) WO2002083624A1 (es)
ZA (1) ZA200307905B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
MXPA04003439A (es) 2001-10-12 2004-07-08 Schering Corp Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
US20040053953A1 (en) 2002-03-18 2004-03-18 Schering Corporation Treatment of chemokine mediated diseases
GB0218326D0 (en) * 2002-08-07 2002-09-11 Glaxo Group Ltd Compounds
CN1720240B (zh) 2002-10-09 2010-10-27 先灵公司 作为cxc-和cc-趋化因子受体配体的噻二唑二氧化物和噻二唑氧化物
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
BRPI0408420A (pt) 2003-04-03 2006-03-21 Merck Patent Gmbh compostos de carbonila
ATE457307T1 (de) 2003-04-18 2010-02-15 Schering Corp Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid
NZ544756A (en) 2003-07-22 2009-09-25 Astex Therapeutics Ltd 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
GB0320983D0 (en) * 2003-09-08 2003-10-08 Biofocus Plc Compound libraries
EP1664007B1 (en) 2003-09-23 2009-12-23 Fermion Oy Preparation of quetiapine
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
JP4939229B2 (ja) 2003-12-19 2012-05-23 シェーリング コーポレイション Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾール
WO2005068460A1 (en) 2003-12-22 2005-07-28 Schering Corporation Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
KR100883476B1 (ko) * 2004-01-30 2009-02-16 쉐링 코포레이션 Ｃｘｃ-케모킨 수용체 리간드의 결정성 다형체
JP2007525521A (ja) * 2004-02-27 2007-09-06 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしてのシクロブテンジオン基含有化合物
AU2005277582A1 (en) 2004-08-16 2006-03-02 The Procter & Gamble Company 2-(amino or substituted amino)-5, 6-substituted phenol compounds, dyeing compositions containing them, and use thereof
EP1634573A1 (en) * 2004-08-16 2006-03-15 The Procter and Gamble Company 2-(Amino or substituted Amino)-5,6-substituted Phenol compounds, dyeing compositions containing them, and use thereof
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
EP2096107A1 (en) 2004-12-23 2009-09-02 GPC Biotech AG Derivatives of squaric acid with anti-proliferative activity
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
CN101253165A (zh) * 2005-06-29 2008-08-27 先灵公司 作为cxc－化学活素受体配体的二取代的二唑
CA2613428A1 (en) 2005-06-29 2007-01-11 Schering Corporation 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands
DE102005035742A1 (de) * 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
HRP20161260T1 (hr) * 2005-11-24 2016-11-18 Dompé Farmaceutici S.P.A. Derivati (r)-arilkilamina i farmaceutski pripravci koji ih sadrže
MX2008015004A (es) * 2006-05-26 2008-12-05 Abbott Lab Inhibidores de cinasas de tipo polo.
AU2007258325B2 (en) 2006-06-12 2013-02-21 Merck Sharp & Dohme Corp. Pharmaceutical formulations and compositions of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders
US20080045489A1 (en) * 2006-07-07 2008-02-21 Jianhua Chao 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
ATE554066T1 (de) * 2007-06-06 2012-05-15 Novartis Ag Entzündungshemmende substituierte cyclobutendionverbindungen
WO2009005801A1 (en) * 2007-07-03 2009-01-08 Schering Corporation Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
MX2010014310A (es) * 2008-06-24 2011-02-15 Topotarget As Derivados de acido escuarico como inhibidores de la nicotinamida.
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (en) * 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
EP2569301A1 (en) 2010-05-12 2013-03-20 Abbvie Inc. Indazole inhibitors of kinase
FR2961695B1 (fr) * 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
CN103442702B (zh) 2011-01-07 2016-02-10 阿勒根公司 黑色素改良组合物及其使用方法
SI2760821T1 (en) 2011-09-02 2018-02-28 Novartis Ag A salt salt of an anti-inflammatory substituted cyclobutenedione compound
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981935B1 (fr) * 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
CN103242210B (zh) * 2012-02-09 2014-09-24 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
AU2013205306B2 (en) 2012-03-16 2015-09-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN103382192A (zh) * 2012-05-04 2013-11-06 同创医药(苏州)有限公司 N-单取代哌嗪衍生物的制备
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
CN103214327A (zh) * 2013-03-22 2013-07-24 郑州泰基鸿诺药物科技有限公司 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN107250116B (zh) 2014-12-23 2020-10-27 艾士盟医疗公司 3,5-二氨基吡唑激酶抑制剂
FR3030515B1 (fr) 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JP2020530848A (ja) * 2017-08-14 2020-10-29 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ３，４−二置換３−シクロブテン−１，２−ジオンおよびその使用
US11052065B2 (en) 2017-09-27 2021-07-06 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist
MA50424A (fr) 2018-01-08 2020-08-26 Chemocentryx Inc Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2
PE20211070A1 (es) 2018-09-21 2021-06-09 Pfizer Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6
CN110041309B (zh) * 2019-04-04 2022-01-28 广东工业大学 一种2-羧基哌嗪连接的他克林-8-氨基(羟基)喹啉衍生物及制备与应用
US20220411367A1 (en) * 2019-10-07 2022-12-29 D. E. Shaw Research, Llc Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers
KR102710925B1 (ko) * 2021-06-01 2024-09-27 부산대학교 산학협력단 신규 스퀘어아마이드 유도체 및 이의 용도
CN118339161B (zh) * 2021-12-10 2025-12-09 正大天晴药业集团股份有限公司 一种异噻唑并[5,4-d]嘧啶类IRAK4抑制剂的制备方法
EP4686469A1 (en) * 2024-07-31 2026-02-04 Dompé farmaceutici SpA Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0692915A (ja) * 1992-07-28 1994-04-05 Sumitomo Metal Ind Ltd １，２−ジアミノシクロブテン−３，４−ジオン誘導体及びその用途
GB9312210D0 (en) * 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
GB9316111D0 (en) * 1993-08-04 1993-09-22 Pfizer Ltd Benzopyrans
US5354763A (en) * 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5466712A (en) * 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
ES2128774T3 (es) * 1994-11-16 1999-05-16 American Home Prod Diaminociclobuten-3,4-dionas.
KR20000022273A (ko) * 1996-06-27 2000-04-25 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 Il-8 수용체 길항제
US5840764A (en) * 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
WO1998033763A1 (en) * 1997-01-30 1998-08-06 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6211220B1 (en) * 1998-11-23 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
CA2351464A1 (en) * 1998-12-14 2000-06-22 Joan E. Sabalski 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
PL348260A1 (en) * 1998-12-16 2002-05-20 Bayer Ag New biphenyl and biphenyl-analogous compounds as integrin antagonists
US6518283B1 (en) * 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
AR033803A1 (es) * 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
WO2001092202A1 (en) * 2000-05-30 2001-12-06 Smithkline Beecham Corporation Il-8 receptor antagonists
EP1351933B1 (en) * 2001-01-16 2006-11-22 SmithKline Beecham Corporation Il-8 receptor antagonists
CA2442480A1 (en) * 2001-03-30 2002-10-10 Katherine L. Widdowson Methods of synthesizing phenol-containing compounds
US20040053953A1 (en) * 2002-03-18 2004-03-18 Schering Corporation Treatment of chemokine mediated diseases

Also Published As

Publication number Publication date
HUP0401783A3 (en) 2005-06-28
CY1109908T1 (el) 2014-09-10
HUP0401783A2 (hu) 2005-01-28
EP1818325B1 (en) 2010-02-24
CN1289471C (zh) 2006-12-13
CA2444031C (en) 2012-02-21
DE60220778T2 (de) 2008-03-06
JP2009179641A (ja) 2009-08-13
AU2006203679A1 (en) 2006-09-14
NZ560453A (en) 2009-03-31
WO2002083624A1 (en) 2002-10-24
KR20030092074A (ko) 2003-12-03
NO330790B1 (no) 2011-07-18
DE60220778D1 (en) 2007-08-02
CN1990457A (zh) 2007-07-04
AR035825A1 (es) 2004-07-14
PT1381590E (pt) 2007-08-06
CA2444031A1 (en) 2002-10-24
HK1107818A1 (en) 2008-04-18
BRPI0208957B1 (pt) 2018-10-09
SI1381590T1 (sl) 2007-10-31
MXPA03009441A (es) 2004-02-12
TW200736196A (en) 2007-10-01
CN1516687A (zh) 2004-07-28
EP1818325A3 (en) 2008-02-13
IL158262A (en) 2012-05-31
ATE458715T1 (de) 2010-03-15
HK1057538A1 (en) 2004-04-08
MY149050A (en) 2013-07-15
NZ529551A (en) 2006-02-24
JP2004532846A (ja) 2004-10-28
KR20100008794A (ko) 2010-01-26
AU2002311841B2 (en) 2006-09-14
NZ543869A (en) 2007-09-28
PL367129A1 (en) 2005-02-21
PL208928B1 (pl) 2011-06-30
JP4499993B2 (ja) 2010-07-14
SK12882003A3 (sk) 2004-06-08
PT1818325E (pt) 2010-05-12
DK1381590T3 (da) 2007-10-22
MY138202A (en) 2009-05-29
BR0208957A (pt) 2004-06-22
SI1818325T1 (sl) 2010-06-30
ES2340207T3 (es) 2010-05-31
CY1109989T1 (el) 2014-09-10
RU2344123C9 (ru) 2009-05-20
SK287598B6 (sk) 2011-03-04
NO20034612D0 (no) 2003-10-15
RU2003133448A (ru) 2005-06-10
DE60235507D1 (de) 2010-04-08
ATE365154T1 (de) 2007-07-15
PL207255B1 (pl) 2010-11-30
JP5294418B2 (ja) 2013-09-18
IL158262A0 (en) 2004-05-12
JP2010053151A (ja) 2010-03-11
EP1381590A1 (en) 2004-01-21
ES2287284T3 (es) 2007-12-16
KR100952531B1 (ko) 2010-04-12
ZA200307905B (en) 2005-03-30
DK1818325T3 (da) 2010-05-31
NO20110050L (no) 2003-12-08
AU2010212484B2 (en) 2012-04-12
RU2344123C2 (ru) 2009-01-20
BRPI0208957B8 (pt) 2021-05-25
EP1818325A2 (en) 2007-08-15
ECSP034809A (es) 2004-02-26
TWI316930B (en) 2009-11-11
AU2010212484A1 (en) 2010-09-09
IL201754A0 (en) 2010-06-16
EP1381590B1 (en) 2007-06-20
CZ20032831A3 (cs) 2004-03-17
NO20034612L (no) 2003-12-08

Similar Documents

Publication Publication Date Title
PE20021084A1 (es) Ciclobuten-1,2-dionas 3,4-di-substituidas como ligandos del receptor de cxc-quimiocina
CY1107008T1 (el) Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
AR035234A1 (es) Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento
PE20050767A1 (es) Amino-benzazoles como inhibidores del receptor p2y1
ECSP056105A (es) Acidos carboxilicos alfa sustituidos como moduladores ppar
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20110588A1 (es) Derivados de benzotiazol como agentes anticancerigenos
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
RU2009108006A (ru) Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов
CY1116119T1 (el) Παραγωγα ισοξαζολο-πυριδινης
AR077485A2 (es) Difenilureas substituidas con carboxiarilo como inhibidores de raf quinasa
NI200700157A (es) Análogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurológicos
AR054799A1 (es) Derivados de oxindol
CR11620A (es) Derivados de Imadazo-[1,2,b]-Piridazina para el Tratamiento de Enfermedad Mediada por Cinosa de Tirosina C-Met
PE20060626A1 (es) Aminas policiclicas sustituidas con arilo como antagonistas de mch1r
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
PE20011186A1 (es) Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo
PE20021011A1 (es) Derivados quinazolinicos como inhibidores de la rho-quinasa
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
EA200700120A1 (ru) Соединения и способы лечения дислипидемии

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed